fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Salmeterol xinafoate & fluticasone propionate

All products: Limited Use (codes 330)

PMS-FluticasonePropionateSalmeterol DPI · DIN 02494515 · 50/250 mcg · inhaler, 60 doses

Limited Use, Reason for Use code 330 requiredMarketed · checked November 18, 2026
StatusLimited Use, Reason for Use code 330 required
Write on scriptReason for Use code 330 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 330
Reason for Use code 330 For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-FluticasonePropionateSalmeterol DPI · DIN 02494515 Manufacturer: Pharmascience Inc.; listing date 2020-04-30 Health Canada: Marketed since 2020-03-05 · brand PMS-FLUTICASONE PROPIONATE/SALMETEROL DPI · ATC R03AK06 SALMETEROL AND FLUTICASONE · form Powder · route Inhalation · ingredients FLUTICASONE PROPIONATE 250 MCG/ACT, SALMETEROL (SALMETEROL XINAFOATE) 50 MCG/ACT · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-FluticasonePropionateSalmeterol DPI: Formulary list price $50.76 per unit (the source does not state the unit; exact figure $50.7600). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02494515)

Source record
DIN 02494515: PMS-FluticasonePropionateSalmeterol DPI Raw flags: sec12=Y, sec3=Y Item: 121200080; group id 237; item number 0422; lccId 00044; manufacturer id PMS Source form: Inh-60 Dose Pk; strength: 50/250mcg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $50.7600; ministry $50.7600 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02494515 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98452
Interchangeable products
Advair Diskus · DIN 02240836 · $50.7600 Wixela Inhub · DIN 02495600 · $50.7600
Shortage status: not checked (no credentials)

Other products in the same Health Canada class (R03A, R03AK): coverage varies; not interchangeable

  • Budesonide + formoterol (Symbicort 100 Turbuhaler): limited Use 330
  • Fluticasone furoate + vilanterol (Breo Ellipta): limited Use 330, limited Use 330, 456
  • Formoterol + mometasone furoate (Zenhale): limited Use 330
  • Salbutamol (Teva-Salbutamol Sterinebs P.F.): general benefit, limited Use 256, 257, 258, 259, limited Use 265, 266, 267, 268, not a benefit
  • Terbutaline (Bricanyl Turbuhaler): general benefit
  • Aclidinium + formoterol (Duaklir Genuair): limited Use 459

8 more in the class list below

Other drugs in the same formulary class (12:12 Sympathomimetic (Adrenergic) Agents) and how they are covered

Matched class: 12:12 Sympathomimetic (Adrenergic) Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: EPINEPHRINE HCL, TERBUTALINE SULFATE Some products covered without a code (check the product listing): ORCIPRENALINE SULFATE, SALBUTAMOL 12:12 Sympathomimetic (Adrenergic) Agents

BUDESONIDE & FORMOTEROL FUMARATE DIHYDRATE

· 2 products · Limited Use, codes 330 · strengths: 100mcg/6mcg, 200mcg/6mcg · Pd Inh-120 Dose Pk

FLUTICASONE FUROATE & VILANTEROL

· 2 products · Limited Use, codes 330, 456 (1), Limited Use, codes 330 (1) · strengths: 100mcg & 25mcg, 200mcg & 25mcg · Blister Pd Inh-30 Dose Pk

MOMETASONE FUROATE & FORMOTEROL FUMARATE DIHYDRATE

· 2 products · Limited Use, codes 330 · strengths: 100mcg & 5mcg, 200mcg & 5mcg · Metered Dose Inh-120 Dose Pk

SALBUTAMOL

· 20 products · Limited Use, codes 265, 266, 267, 268 (4), Listed, not a benefit (8), Limited Use, codes 256, 257, 258, 259 (1), General benefit (7) · strengths: 1mg/mL, 2mg/mL, 5mg/mL, 100mcg/Metered Dose, 2mg, 4mg · Inh Sol- 2.5mL Pk, Inh Sol-10mL Pk, Inh-200 dose Pk, Tab

TERBUTALINE SULFATE

· 2 products · General benefit · strengths: 0.5mg/Dose · Inh-100 Dose Pk, Inh-120 Dose Pk

ACLIDINIUM BROMIDE & FORMOTEROL FUMARATE DIHYDRATE

· 1 products · Limited Use, codes 459 · strengths: 400mcg & 12mcg · Metered Dose Pd Inh-60 Dose Pk

BUDESONIDE&GLYCOPYRRONIUM (GLYCOPYRRONIUM BROMIDE)&FORMOTEROL FUMARATE DIHYDRATE

· 1 products · Limited Use, codes 638 · strengths: 160mcg & 7.2mcg & 5mcg/Act · Metered Dose Inh-120 Dose Pk

FLUTICASONE FUROATE & UMECLIDINIUM BROMIDE & VILANTEROL TRIFENATATE

· 1 products · Limited Use, codes 567 · strengths: 100mcg & 62.5mcg & 25mcg · Pd Inh-30 Dose Pk

FORMOTEROL FUMARATE

· 1 products · Limited Use, codes 132 · strengths: 12mcg/Cap · Inh Pd-Device Pk

FORMOTEROL FUMARATE DIHYDRATE

· 2 products · Limited Use, codes 132 · strengths: 6mcg/Metered Dose, 12mcg/Metered Dose · Pd Inh-60 Dose Pk

INDACATEROL

· 1 products · Limited Use, codes 443 · strengths: 75mcg · Inh Pd-Cap

INDACATEROL & GLYCOPYRRONIUM

· 1 products · Limited Use, codes 459 · strengths: 110mcg & 50mcg · Inh Pd-Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 12:12 and 4 more
Full class listing Related classes: 12:04 Parasympathomimetic (Cholinergic) Agents, 12:08 Parasympatholytic (Cholinergic Blocking) Agents, 12:20 Skeletal Muscle Relaxants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: copd
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. FLUTICASONE FUROATE & VILANTEROL · Limited Use, codes 330, 456 (1), Limited Use, codes 330 (1) BREO ELLIPTA 100/25 mcg once daily is the only strength indicated for the treatment of COPD. PM: https://pdf.hres.ca/dpd_pm/00049111.PDF; date January 7, 2019; DIN 02408872; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Asthma ADVAIR/ADVAIR DISKUS (fluticasone propionate/salmeterol) is a combination of an inhaled corticosteroid (ICS) and a long-acting beta2-adrenergic agonist (LABA) indicated for the maintenance treatment of asthma, in patients with reversible obstructive airways disease. ADVAIR/ADVAIR DISKUS should be prescribed for patients not adequately controlled on a long-term asthma control medication, such as an ICS, or whose disease severity clearly warrants treatment with both an ICS and a LABA. ADVAIR/ADVAIR DISKUS is not indicated for patients whose asthma can be managed by occasional use of a rapid onset, short duration, inhaled beta2-agonist, or for patients whose asthma can be successfully managed by inhaled corticosteroids along with occasional use of a rapid onset, short duration, inhaled beta2-agonist. Page 3 of 70 ADVAIR/ADVAIR DISKUS should not be used as a rescue medication. To relieve acute asthmatic symptoms, a rapid onset, short duration inhaled bronchodilator (e.g. salbutamol) should be used. Chronic Obstructive Pulmonary Disease (COPD) ADVAIR DISKUS 250 a… https://pdf.hres.ca/dpd_pm/00056976.PDF PM date: June 17, 2020 Source product: ADVAIR 100 DISKUS; DIN 02240835; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18